DISCOVER

Our News

November 6, 2023 - Carthera announces the signing of a strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company, for the supply of carboplatin.

September 18, 2023 – Medical device industry executive with 30+ years expertise brings wealth of experience in product development and commercial launches to support Carthera’s future growth.

June 27, 2023 - New funds will help launch pivotal multicenter trial in patients with recurrent glioblastoma and advance clinical pipeline.

May 3, 2023 - Four-to six-fold increase in drug concentrations measured in human brain after blood-brain barrier opening with SonoCloud-9 System

March 13, 2023 - Carthera and FDA aligned on key aspects of proposed pivotal trial design.

June 22, 2022 - Breakthrough Status allows for enhanced interaction with FDA and recognizes SonoCloud® as innovative and promising approach for treatment of recurrent glioblastoma.

June 9, 2021 - SonoCloud® device can enhance delivery of CAR-T therapies and penetration of checkpoint inhibitors into the brain of preclinical glioma models.

December 16, 2020 - The trial will recruit up to 39 patients with recurrent glioblastoma to test the SonoCloud-9 device in combination with Abraxane®.

September 14, 2020 - Carthera announces that it has been selected by the EIC (European Innovation Council) pilot gas pedal program for the development of its DOMEUS project.

June 8, 2020 - The SoniMel study aims to demonstrate safety of using the SonoCloud® technology with checkpoint inhibitors for the treatment of brain metastases from melanoma.